Experienced in Lung Adenocarcinoma

Dr. Barry W. Sigal

Pulmonary Medicine | Intensive Care Medicine
3001 Lyndhurst Ave, 
Winston-salem, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Lung Adenocarcinoma
3001 Lyndhurst Ave, 
Winston-salem, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Barry Sigal is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Winston-salem, North Carolina. Dr. Sigal is rated as an Experienced provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, Pulmonary Fibrosis, and Advanced Bronchoscopy. Dr. Sigal is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Critical Care Medicine in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

3001 Lyndhurst Ave, Winston-salem, NC 27103
Other Locations
171 Ashley Ave, Charleston, SC 29425

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Enrollment Status: Recruiting
Publish Date: October 14, 2025
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease
Enrollment Status: Terminated
Publish Date: February 14, 2024
Intervention Type: Drug, Other
Study Drug: Deupirfenidone
Study Phase: Phase 2
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study
Enrollment Status: Completed
Publish Date: March 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
Enrollment Status: Completed
Publish Date: October 14, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study
Enrollment Status: Withdrawn
Publish Date: April 22, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

2 Total Publications

Assessing a biomarker's ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study.
Assessing a biomarker's ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study.
Journal: PloS one
Published: February 13, 2023
Similar Doctors
Advanced in Lung Adenocarcinoma
Dr. Ahmed Elnaggar
Intensive Care Medicine
Advanced in Lung Adenocarcinoma
Dr. Ahmed Elnaggar
Intensive Care Medicine

Piedmont Healthcare Endoscopy Center

208 Old Mocksville Rd, 
Statesville, NC 
 (35.1 miles away)
704-838-8240
Languages Spoken:
English
See accepted insurances

Ahmed Elnaggar is an Intensive Care Medicine provider in Statesville, North Carolina. Dr. Elnaggar is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Atypical Pneumonia, Hospital-Acquired Pneumonia, and Advanced Bronchoscopy.

Douglas Mcquaid
Advanced in Lung Adenocarcinoma
Dr. Douglas Mcquaid
Intensive Care Medicine
Advanced in Lung Adenocarcinoma
Dr. Douglas Mcquaid
Intensive Care Medicine

Ahwfb Pulmonology-Westchester

1814 Westchester Dr Ste 202, 
High Point, NC 
 (16.2 miles away)
336-802-2090
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Mcquaid is an Intensive Care Medicine provider in High Point, North Carolina. Dr. Mcquaid is rated as an Advanced provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Large-Cell Lung Carcinoma, EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Lung Carcinoma, and Gastrostomy.

Advanced in Lung Adenocarcinoma
Dr. Christina Bellinger
Pulmonary Medicine
Advanced in Lung Adenocarcinoma
Dr. Christina Bellinger
Pulmonary Medicine

Quest Diagnostics-Winston-Salem Stat Lab

200 Charlois Blvd, 
Winston Salem, NC 
 (0.7 miles away)
336-716-4649
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christina Bellinger is a Pulmonary Medicine provider in Winston Salem, North Carolina. Dr. Bellinger is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. Her top areas of expertise are Lung Nodules, Lymphofollicular Hyperplasia, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sigal's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 31 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile